AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-64. Canceled

65. (Previously Presented) A compound of formula I,



I

wherein:

R^1 represents Het^1, $R^{1a}C(O)$- or D-A-N(H)-$[Q]_n$-C(O)-E-C(O)-;

R^{1a} represents:

H,

aryl optionally substituted by one or more substituents selected from the group consisting of OH, halo, cyano, nitro, $N(R^{3a})R^{3b}$, C_{1-4} alkyl and C_{1-4} alkoxy,

aromatic or part-aromatic C_{13-14} tricyclic carbocyclyl optionally substituted by one or more substituents selected from the group consisting of OH, halo, cyano, nitro, $N(R^{3a})R^{3b}$, C_{1-4} alkyl and C_{1-4} alkoxy, and when the C_{13-14} tricyclic carbocyclyl is part-aromatic, a non-aromatic part of the C_{13-14} tricyclic carbocyclyl is optionally substituted by one or two oxo groups or

C_{1-12} alkyl optionally substituted and/or terminated by one or more substituents selected from the group consisting of halo and aryl, wherein the aryl is optionally substituted by one or more substituents selected from the group consisting of OH, halo, cyano, nitro, $N(R^{3a})R^{3b}$, C_{1-4} alkyl and C_{1-4} alkoxy;

A represents C_{2-6} alkylene or A^1-C(O)N(H)-A^2, wherein A^2 is attached to D;

A^1 represents C_{1-4} alkylene;

A^2 represents C_{2-5} alkylene;

D represents $-N(R^{2a})R^{2b}$, $-C(=NR^{2c})N(R^{2d})R^{2e}$ or $-N(R^{2f})C(=NR^{2g})N(H)R^{2h}$;

R^{2a} and R^{2b} independently represent H, C_{1-6} alkyl, or Het^2, or R^{2a} and R^{2b} together represent $(CH_2)_{3-6}$, wherein the $(CH_2)_{3-6}$ is optionally interrupted by NR^4 and/or is optionally substituted by one or more C_{1-4} alkyl groups;

R^4 represents H, C_{1-6} alkyl or Het^3;

R^{2c} to R^{2h} independently represent H or C_{1-6} alkyl;

E represents $-E^1-Het^4-$, E^{2a}, $-(CH_2)_{0-3}N(H)C(O)-E^{2b}-C(O)N(H)(CH_2)_{0-3}-$ or is represented by the formula



E^3 represents $(CH_2)_{1-2}$, CH=CH, CH=N, $CH_2-N(R^a)$, $(CH_2)_{0-1}C(O)$, $(CH_2)_{0-1}O$ or $(CH_2)_{0-1}S$;

R^a represents H or C_{1-6} alkyl;

E^1 represents $(CH_2)_{0-2}$ or CH=CH;

E^{2a} and E^{2b} independently represent C_{2-4} alkenylene, C_{3-6} cycloalkylene, phenylene or naphthylene;

Het^1 to Het^4 independently represent four- to twelve-membered heterocyclic groups containing one or more heteroatoms selected from N, O and S, which heterocyclic groups are optionally substituted by one or more substituents selected from the group consisting of =O, OH, halo, cyano, nitro, $N(R^{3a})R^{3b}$, C_{1-4} alkyl and C_{1-4} alkoxy;

R^{3a} and R^{3b} independently represent H or C_{1-4} alkyl, or R^{3a} represents $-C(O)R^5$;

R^5 represents H or C_{1-4} alkyl;

n represents 2, 3, 4 or 5;

each individual Q independently represents a structure represented by formula Ia, Ib, Ic, Id, Ie or If



Ia



Ib



Ic



Id



Ie



If

wherein

R^6 represents H or C_{1-6} alkyl;

R^7 represents C_{1-12} alkyl;

R^8, R^9, R^{10} and R^{11} independently represent H or C_{1-12} alkyl;

G represents CH or N;

L represents O or S; and

p, q and r independently represent 0, 1, 2 or 3;

provided that the compound comprises at least one structure represented by formula Ib, Ic, Id, Ie or If in which R^6 or R^7, R^8, R^9, R^{10} or R^{11}, respectively, represents branched, cyclic or part cyclic C_{3-5} alkyl; or a pharmaceutically acceptable derivative thereof.

66. (Previously Presented) A compound as claimed in Claim 65, wherein:

R^{1a} represents H or C_{1-12} alkyl optionally substituted and/or terminated by one or more substituents selected from halo and aryl optionally substituted by one or more substituents selected from the group consisting of OH, halo, cyano, nitro, $N(R^{3a})R^{3b}$, C_{1-4} alkyl and C_{1-4} alkoxy; and

the compound comprises at least one structure represented by formula Ib, Ic, Id, Ie or If in which R^7, R^8, R^9, R^{10} or R^{11}, respectively, represents branched, cyclic or part cyclic C_{3-5} alkyl.

67. (Previously Presented) A compound as claimed in Claim 65, wherein aryl is phenyl or naphthyl.

68. (Previously Presented) A compound as claimed in Claim 65, wherein alkyl and alkoxy groups are:

(a) straight-chain;

(b) branched-chain and/or cyclic; or

(c) part cyclic/acyclic.

69. (Previously Presented) A compound as claimed in Claim 65, wherein alkyl and alkoxy groups are:

(a) saturated or unsaturated;

(b) interrupted by one or more oxygen and/or sulfur atoms; and/or

(c) unless otherwise specified, substituted by one or more halo atoms.

70. (Previously Presented) A compound as claimed in Claim 65, which is a compound of formula II,



II

wherein

R^1 represents Het^1, $R^{1a}C(O)$- or D-A-N(H)-Q^3-Q^2-Q^1-C(O)-E-C(O)-;

Q^1 is absent or represents a structure represented by formula Ia, Ib, Ic, Id, Ie or If;

Q^2 represents a structure represented by formula Ib, Ie or If; and

Q^3 represents a structure represented by formula Ib, Id, Ie or If, provided that:

(a) at least one of Q^1, Q^2 and Q^3 represents a structure represented by formula Id, Ie or If; and

(b) at least one of R^6 or R^7, R^8, R^9, R^{10} and R^{11} represents branched, cyclic or part cyclic C_{3-5} alkyl, or a pharmaceutically acceptable derivative thereof.

71. (Previously Presented) A compound as claimed in Claim 65, wherein the compound comprises:

(a) at least one structure represented by formula Ib in which G represents N and R^6 represents branched, cyclic or part cyclic C_{3-5} alkyl;

(b) at least one structure represented by formula Id in which p represents 0 and R^9 represents branched, cyclic or part cyclic C_{3-5} alkyl; and/or

(c) at least one structure represented by formula Ie in which q represents 0 and R^{10} represents branched, cyclic or part cyclic C_{3-5} alkyl.

72. (Previously Presented) A compound as claimed in Claim 65, wherein each of the at least one branched, cyclic or part cyclic C_{3-5} alkyl groups independently represents isopropyl, cyclopropylmethyl, isopentyl or cyclopentyl.

73. (Previously Presented) A compound as claimed in Claim 65, wherein the compound comprises at least one structure represented by formula Ib, Ic, Id, Ie or If in which R^7, R^8, R^9, R^{10} or R^{11}, respectively, represents isopropyl.

74. (Previously Presented) A compound as claimed in Claim 65, which compound comprises at least one structure represented by the formula



.

75-94. (Canceled)

95. (Previously Presented) A compound of formula IIa,



IIa

wherein

R^1 represents

a nine-membered aromatic heterocycle containing two heteroatoms selected from N, O and S,

$R^{1a}C(O)$- or

D-A-N(H)-Q^3-Q^2-Q^1-C(O)-E-C(O)-;

R^{1a} represents

H,

phenyl optionally substituted by C_{1-2} alkyoxy,

9,10-dioxo-9,10-dihydroanthracenyl optionally substituted by C_{1-2} alkoxy,

saturated, optionally branched C_{1-6} alkyl or

saturated C_{1-3} *n*-alkyl, terminated by phenyl optionally substituted by C_{1-2} alkoxy;

A represents saturated C_{2-4} alkylene or $(CH_2)_{1-3}$-C(O)N(H)-$(CH_2)_{2-4}$;

D represents $-N(R^{2a})R^{2b}$;

R^{2a} and R^{2b} independently represent

C_{1-3} alkyl or a nine- or ten-membered aromatic heterocycle containing one to three heteroatoms selected from N, O and S, or

R^{2a} and R^{2b} together represent $(CH_2)_{3-5}$ optionally interrupted by NR^4;

R^4 represents

C_{1-3} alkyl or a nine- or ten-membered aromatic heterocycle containing one to three heteroatoms selected from N, O and S;

E represents

-(2,5-indolyl-,

$-(CH_2)_{0-2}$-(2,6-indolyl)-,

-CH=CH-(2,6-indolyl)-,

trans-ethenylene,

trans-cyclopropylene,

1,3- or 1-4-phenylene,

$-CH_2N(H)C(O)$-(1,3- or 1,4-phenylene)-$C(O)N(H)CH_2$-,

or one of the following structures



,

Q^1 is absent or represents a structure represented by formula Ia, Ib, Ic, Id, Ie or If;

Q^2 represents a structure represented by formula Ib, Ie or If;

Q^3 represents a structure represented by formula Ib, Id, Ie or If;

wherein the structures of formulae Ia, Ib, Ic, Id, Ie and If are as follows



Ia

Ib



Ic



Id



Ie



If

wherein

R^6 represents H or, when G represents N, R^6 represents H or branched, cyclic or part cyclic C_{3-5} alkyl;

R^7, R^8, R^9, R^{10} and R^{11} independently represent saturated, optionally branched C_{1-6} alkyl or R^8 represents H;

provided that the compound comprises at least one structure represented by formula Ie in which R^{10} represents branched, cyclic or part cyclic C_{3-5} alkyl.

96. (Previously Presented) A compound as claimed in Claim 95 wherein the compound comprises at least one structure represented by formula Ie in which R^{10} represents cyclopropylmethyl, isopentyl, cyclopentyl or isopropyl.

97. (Previously Presented) A compound as claimed in Claim 95 wherein the compound comprises at least one structure represented by formula Ie in which R^{10} represents isopropyl.

98. (Previously Presented) A compound of formula IIb,



IIb

wherein

R^1 represents

a nine-membered aromatic heterocycle containing two heteroatoms selected from N, O and S,

HC(O)-,

(methoxyphenyl)C(O)-,

(9,10-dioxo-9,10-dihydroanthracenyl)C(O)-,

(saturated C_{1-3} alkyl) C(O)-,

(methoxyphenylacetyl)C(O)-, or

$(CH_3)_2N$-A-N(H)-Q^3-Q^2-Q^1-C(O)-E-C(O)-;

A represents saturated C_{2-4} *n*-alkylene or $(CH_2)_2$-C(O)N(H)-$(CH_2)_3$;

E represents $-CH_2N(H)C(O)$-(1,3-phenylene)-$C(O)N(H)CH_2$-;

Q^1 is absent or represents a structure represented by formula Ia, Ib, Ic, Id, Ie or If;

Q^2 represents a structure represented by formula Ib, Ie or If;

Q^3 represents a structure represented by formula Ib, Id, Ie or If;

wherein the structures of formulae Ia, Ib, Ic, Id, Ie and If are as follows



Ia



Ib



Ic



Id



Ie



If

wherein

R^6 represents H or, when G represents N, R^6 represents H or branched, cyclic or part cyclic C_{3-5} alkyl;

R^7, R^9, R^{10} and R^{11} independently represent saturated, optionally branched C_{1-3} alkyl;

provided that the compound comprises at least one structure represented by formula Ie in which R^{10} represents branched, cyclic or part cyclic C_{3-5} alkyl.

99. (Previously Presented) A compound as claimed in Claim 98, wherein the compound comprises at least one structure represented by formula Ie in which R^{10} represents cyclopropylmethyl, isopentyl, cyclopentyl or isopropyl.

100. (Previously Presented) A compound as claimed in Claim 98, wherein the compound comprises at least one structure represented by formula Ie in which R^{10} represents isopropyl.

101. (Previously Presented) A compound as claimed in Claim 65, which compound is selected from the following:

(i) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopropyl-1-*H*-pyrrol-3-yl]-4-[(3,3-dimethylbutanoyl)amino]-1-methyl-1*H*-pyrrole-2-carboxamide;

(ii) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopropyl-1*H*-pyrrol-3-yl]-4-(formylamino)-1-methyl-1*H*-pyrrole-2-carboxamide;

(iii) *N*-[3-(Dimethylamino)propyl]-2-({[4-({[4-(formylamino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}amino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}-amino)-5-isopropyl-1,3-thiazole-4-carboxamide;

(iv) *N*-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-isopropyl-1*H*-pyrrol-3-yl]-4-({[4-(formylamino)-1-isopropyl-1*H*-pyrrol-2-yl]carbonyl}-amino)-1-isopropyl-1*H*-pyrrole-2-carboxamide

(v) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl]-4-(formyl-amino)-1-isopentyl-1*H*-pyrrole-2-carboxamide;

(vi) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-isopropyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-4-(formyl-amino)-1-isopropyl-1*H*-pyrrole-2-carboxamide;

(vii) *N*-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-2-({[4-(formylamino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}-amino)-5-isopropyl-1,3-thiazole-4-carboxamide;

(viii) 4-({[4-(Formylamino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}amino)-1-iso-propyl-*N*-[1-methyl-5-({[3-(4-morpholinyl)propyl]amino}carbonyl)-1*H*-pyrrol-3-yl]-1*H*-pyrrole-2-carboxamide;

(ix) 4-(Formylamino)-*N*-[1-isopropyl-5-({[1-methyl-5-({[3-(1-pyrrolidinyl)-propyl]amino}carbonyl)-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-1-methyl-1*H*-pyrrole-2-carboxamide;

(x) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl]-4-(formylamino)-1-methyl-1*H*-pyrrole-2-carboxamide;

(xi) 2-(Acetylamino)-*N*-[5-({[5-({[3-(dimethylamino)propyl]amino}-carbonyl)-1-methyl-1*H*-pyrrol-3-

yl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-5-isopropyl-1,3-thiazole-4-carboxamide;

(xii) 2-(Acetylamino)-*N*-[5-({[4-({[3-(dimethylamino)propyl]amino}-carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-5-isopropyl-1,3-thiazole-4-carboxamide;

(xiii) 2-(Acetylamino)-*N*-(5-{[(3-{[3-(dimethylamino)propyl]amino}-3-oxo-propyl)amino]carbonyl}-1-methyl-1*H*-pyrrol-3-yl)-5-isopropyl-1,3-thiazole-4-carboxamide;

(xiv) N^1,N^3-Bis(2-{[5-({[4-({[3-(dimethylamino)propyl]amino}carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-amino}-2-oxoethyl)isophthalamide;

(xv) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopropyl-1*H*-pyrrol-3-yl]-4-(acetylamino)-1-methyl-1*H*-pyrrole-2-carboxamide;

(xvi) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl]-4-(acetyl-amino)-1-methyl-1*H*-pyrrole-2-carboxamide;

(xvii) N^2,N^5-Bis[5-({[4-({[3-(dimethylamino)propyl]amino}carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-1*H*-indole-2,5-dicarboxamide;

(xviii) N^2,N^5-Bis[1-isopentyl-5-({[1-methyl-5-({[3-(4-morpholinyl)propyl]-amino}carbonyl)-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-1*H*-indole-2,5-dicarboxamide;

(xix) N^2,N^5-Bis[5-({[5-({[3-(dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl]-1*H*-indole-2,5-dicarboxamide;

(xx) N^2,N^5-Bis[1-isopentyl-5-({[1-methyl-5-({[3-(4-methyl-1-piperazinyl)-propyl]amino}carbonyl)-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-1*H*-indole-2,5-dicarboxamide;

(xxi) 2-({[4-({[4-(Acetylamino)-1-methyl-1*H*-imidazol-2-yl]carbonyl}-amino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}amino)-*N*-[3-(dimethylamino)-propyl]-5-isopropyl-1,3-thiazole-4-carboxamide;

(xxii) 4-(Acetylamino)-*N*-[1-isopentyl-5-({[1-methyl-5-({[3-(4-methyl-1-piperazinyl) propyl]amino}carbonyl)-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-1-methyl-1*H*-pyrrole-2-carboxamide;

(xxiii) *N*-[1-Isopentyl-5-({[1-methyl-5-({[3-(4-methyl-1-piperazinyl)-propyl]amino}carbonyl)-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-4-[(3-methoxybenzoyl)amino]-1-methyl-1*H*-pyrrole-2-carboxamide;

(xxiv) *N*-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-4-({[5-(formylamino)-2-methyl-3-thienyl]carbonyl}amino)-1-isopentyl-1*H*-pyrrole-2-carboxamide;

(xxv) *N*-[5-({[5-({[3-(dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-5-isopropyl-2-[(3-methoxybenzoyl)amino]-1,3-thiazole-4-carboxamide;

(xxvi) *N*-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-4-{[(5-{[(9,10-dioxo-9,10-dihydro-2-anthracenyl)carbonyl]-amino}-2-methyl-3-thienyl)carbonyl]amino}-1-isopentyl-1*H*-pyrrole-2-carboxamide;

(xxvii) *N*-[1-(Cyclopropylmethyl)-5-({[5-({[3-(dimethylamino)propyl]-amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-4-(formylamino)-1-methyl-1*H*-pyrrole-2-carboxamide;

(xxviii) 1-Cyclopentyl-*N*-[5-({[3-(dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-4-({[4-(formylamino)-1-methyl-1*H*-pyrrol-2-yl]-carbonyl}-amino)-1*H*-pyrrole-2-carboxamide;

(xxix) N^2,N^7-Bis[5-({[4-({[3-(dimethylamino)propyl]amino}carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-9,10-dihydro-2,7-phenanthrenedicarboxamide;

(xxx) 4-(Formylamino)-*N*-[1-isopentyl-5-({[1-methyl-5-({[3-(4-methyl-1-piperazinyl)propyl]amino}carbonyl)-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-1-methyl-1*H*-pyrrole-2-carboxamide;

(xxxi) 4-(Acetylamino)-*N*-[1-isopentyl-5-({[1-methyl-5-({[3-(4-morpholinyl)propyl]amino}carbonyl)-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-1-methyl-1*H*-pyrrole-2-carboxamide;

(xxxii) 4-(Formylamino)-*N*-[1-isopentyl-5-({[1-methyl-5-({[3-(4-morpholinyl)propyl]amino}carbonyl)-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-1-methyl-1*H*-pyrrole-2-carboxamide;

(xxxiii) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl]-4-[(3-methoxybenzoyl)amino]-1-methyl-1*H*-pyrrole-2-carboxamide; and

(xxxiv) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl]-4-{[(4-methoxyphenyl)acetyl] amino}-1-methyl-1*H*-pyrrole-2-carboxamide.

102. (Previously Presented) A compound as claimed in Claim 101 which is:

(a) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopropyl-1*H*-pyrrol-3-yl]-4-(formylamino)-1-methyl-1*H*-pyrrole-2-carboxamide;

(b) *N*-[3-(Dimethylamino)propyl]-2-({[4-({[4-(formylamino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}amino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}-amino)-5-isopropyl-1,3-thiazole-4-carboxamide;

(c) *N*-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-2-({[4-(formylamino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}-amino)-5-isopropyl-1,3-thiazole-4-carboxamide;

(d) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl]-4-(formylamino)-1-methyl-1*H*-pyrrole-2-carboxamide;

(e) N^2,N^5-Bis[1-isopentyl-5-({[1-methyl-5-({[3-(4-morpholinyl)propyl]-amino}carbonyl)-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-1*H*-indole-2,5-dicarboxamide;

(f) *N*-[1-(Cyclopropylmethyl)-5-({[5-({[3-(dimethylamino)propyl]-amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-4-(formylamino)-1-methyl-1*H*-pyrrole-2-carboxamide; or

(g) N^2,N^7-Bis[5-({[4-({[3-(dimethylamino)propyl]amino}carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-9,10-dihydro-2,7-phenanthrenedicarboxamide.

103. (Previously Presented) A compound as claimed in Claim 95 which is *N*-[3-(dimethylamino)-propyl]-2-({[4-({[4-(formylamino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}-amino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}amino)-5-isopropyl-1,3-thiazole-4-carboxamide.

104. (Previously Presented) A compound as claimed in Claim 65, which binds to and/or has specificity for DNA sequences that contain at least one GC base pairing.

105. (Previously Presented) A compound as claimed in Claim 95 or 98, which binds to and/or has specificity for DNA sequences that contain at least one GC base pairing, provided that the compound comprises at least one structure represented by formula Id, Ie or If.

106. (Previously Presented) A compound as claimed in Claim 65 which has different binding affinities at different minor groove binding sites in double-stranded DNA molecules having more than one minor groove binding site.

107. (Previously Presented) A compound as claimed in Claim 106, wherein the different minor groove binding sites comprise solely AT base pairs.

108. (Previously Presented) A pharmaceutical formulation including a compound as defined in Claim 65 in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier.

Claims 109-118 (Canceled).

119. (Previously Presented) A method of stabilising a DNA duplex formed between first and second single strands of DNA, which method comprises contacting that DNA duplex with a compound as defined in Claim 65.

120. (Previously Presented) A method of enhancing the difference in melting temperatures between first and second DNA duplexes, wherein each DNA duplex is formed from a first single strand of DNA that is the same in each duplex and a second single strand of DNA that is different in each duplex, which method comprises contacting each DNA duplex with a compound as defined in Claim 65.

121. (Previously Presented) A process for the preparation of compounds of formula I as defined in Claim 65 which comprises:

(a) reaction of a compound of formula III,



III

wherein A^a represents A or, when a represents 0, then A^a represents A or A^2, a is as defined below, with a compound of formula IV,



IV

wherein A^b represents a direct bond or $-A^1-C(O)-$, L^1 represents a leaving group, a and b both represent integers from 0 to 5, the sum of a and b being 2, 3, 4 or 5;

(b) for compounds of formula I in which R^1 represents $D-A-N(H)-[Q]_n-C(O)-E-C(O)-$, reaction of two equivalents of a compound of formula V,



V

with a compound of formula VI,

$$L^2-C(O)-E-C(O)-L^2 \qquad VI$$

wherein L^2 represents a leaving group, the two L^2 groups being the same or different; or

(c) deprotection of a protected derivative of a compound of formula I.

122. (Previously Presented) A compound of formula V, as defined in Claim 121, or a protected derivative thereof.